VBY-376, a small-molecule CTSB inhibitor for hepatic fibrosis/NASH, demonstrates robust preclinical efficacy, favorable preliminary human safety, and progress into Phase II trials [60]. The gene discussed is CTSB; the disease is metabolic dysfunction-associated steatohepatitis.